Noda Takehiro, Nagano Hiroaki, Wada Hiroshi, Marubashi Shigeru, Miyamoto Atsushi, Takeda Yutaka, Umeshita Koji, Dono Keizo, Ohsuga Keigo, Kim Tonsok, Tomoda Kaname, Nakamura Hironobu, Monden Morito
Dept. of Surgery, Graduate School of Medicine, Osaka University.
Gan To Kagaku Ryoho. 2006 Sep;33(9):1221-5.
Hepatic arterial infusion (HAI) chemotherapy has been selected as a therapeutic option for highly advanced hepatocellular carcinoma (HCC) with tumor thrombi in major portal branches or intrahepatic metastases. Conventional therapies have no clinical effect on highly advanced HCC. Recent advances of an implanted portcatheter system have facilitated repeated arterial infusion of chemotherapeutic agents, and HAI chemotherapy with several anticancer drugs provides a useful choice for advanced HCC. In various regimens of HAI chemotherapy, low-dose cisplatin and 5-fluorouracil (5-FU) therapy or combination therapy of interferon (IFN)-alpha/5-FU have been reported to improve the response rates for advanced HCC. However, the survival benefit of HAI chemotherapy may be affected by liver function. None of these regimens have been proved to be the standard for HAI chemotherapy. We previously reported that the beneficial effects of combination therapy of IFN-alpha/5-FU for advanced HCC. IFN-alpha/5-FU combination therapy may be a promising treatment modality for advanced HCC.
肝动脉灌注（HAI）化疗已被选为治疗伴有主要门静脉分支肿瘤血栓或肝内转移的高度进展性肝细胞癌（HCC）的一种治疗选择。传统疗法对高度进展性HCC无临床疗效。植入式导管系统的最新进展促进了化疗药物的重复动脉灌注，并且使用几种抗癌药物的HAI化疗为进展期HCC提供了一种有用的选择。在HAI化疗的各种方案中，据报道低剂量顺铂和5-氟尿嘧啶（5-FU）疗法或干扰素（IFN）-α/5-FU联合疗法可提高进展期HCC的缓解率。然而，HAI化疗的生存获益可能受肝功能影响。这些方案均未被证明是HAI化疗的标准方案。我们之前报道了IFN-α/5-FU联合疗法对进展期HCC的有益作用。IFN-α/5-FU联合疗法可能是进展期HCC一种有前景的治疗方式。
